Vicagrel not checked
Jiangsu vcare pharmaceutical technology co., LTD
FollowEvery change as it happens, and a Monday email
Trials
1 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.”In the company’s words, NCT06577519 on ClinicalTrials.gov
Other drugs for Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
- DalcetrapibDalCor Pharmaceuticals · Phase 3
- OrticumabAbcentra · Phase 2
- CG-0255Shanghai CureGene Pharmaceutical Co., Ltd. · Phase 1
- InclisiranNovartis · Marketed (Phase 4 trial)
Coming up1
- 30 DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Dec 2026 | Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | |
| Phase 1Completed | 20 Oct 2021 | A Clinical Trial to Evaluate the Effect of Food on PK and PD of Vicagrel Capsules in Healthy Adult Subjects | |
| Phase 1Completed | 3 Nov 2022 | PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers | |
| Phase 1Completed | 22 Aug 2025 | Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026